Study of Autologous Chondrocyte Implantation to Treat Knee Cartilage Defects in Patients Aged 15 to 50

What this Trial Is About

This research aims to evaluate the effectiveness and safety of using a patients own cartilage cells, called autologous chondrocytes, to treat knee cartilage defects such as articular cartilage defects, chondral defects, and osteochondritis. It is a prospective, interventional study focused on improving knee function and quality of life for patients with specific cartilage lesions that have not responded to previous treatments. The study involves taking a biopsy from the patient, growing their cartilage cells in a laboratory, and then injecting these cells at a dose of 2 million cells per square centimeter directly into the cartilage defect in the knee. After implantation, participants follow a strict rehabilitation protocol for 12 months. Follow-up visits are scheduled at 6 weeks, 3 months, 6 months, and 12 months to monitor progress and safety. Participants will undergo assessments including MRI scans evaluated by the MOCART scoring system to observe cartilage repair, as well as orthopedic evaluations using scores like KOOS, IKDC, and the SF-12 survey to measure knee function, pain, and quality of life. Safety is closely monitored by tracking serious adverse events and infections related to the implantation. The total study duration includes one year of follow-up after the cell implantation procedure.

Introduction of ACI for Cartilage Repair